Cefcanel
Cefcanel is an orally active cephalosporin and antibacterial agent. Cefcanel inhibits growth of methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, Haemophilus influenzae, Moraxella catarrhalis. Cefcanel acts as a substrate hydrolyzed by TEM-1, TEM-3, and Moraxella Bro-1 beta-lactamases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 41952-52-7
- 分子式: C19H18N4O5S3
- 分子量:478.57
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Beta-lactamase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
Cefcanel (18-20 h) exhibits potent in vitro activity against a variety of aerobic Gram-positive bacteria, including methicillin-sensitive *Staphylococcus aureus* (MIC90 1 μg/mL) and methicillin-sensitive *Staphylococcus epidermidis* (MIC90 1 μg/mL)[1].
Cefcanel (18-20 h) exhibits variable in vitro activity against aerobic Gram-negative bacteria. It shows potent activity against *Klebsiella pneumoniae* (MIC90 2 μg/mL), *Citrobacter diversus* (MIC90 2 μg/mL), *Aeromonas hydrophila* (MIC90 1 μg/mL), *Haemophilus influenzae* (MIC90 1 μg/mL) and *Moraxella catarrhalis* (MIC90 1 μg/mL), but is inactive against *Serratia marcescens*, *Pseudomonas aeruginosa* and *Acinetobacter calcoaceticus*[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 41952-52-7
-
分子量 478.57
-
分子式 C19H18N4O5S3
-
SMILES
OC(C1=C(CSC2=NN=C(C)S2)CS[C@@]([C@@H]3NC([C@@H](C4=CC=CC=C4)O)=O)([H])N1C3=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Cefcanel
- 41952-52-7
- Bacterial
- Beta-lactamase
- Escherichia coli
- methicillin-susceptible Staphylococcus aureus
- Haemophilus influenzae
- Clostridium perfringens
- Streptococcus pyogenes
- Moraxella catarrhalis
- Streptococcus pneumoniae
- beta-lactamases
- methicillin-susceptible Staphylococcus epidermidis
- Klebsiella pneumoniae
- Inhibitor
- inhibitor
- inhibit